HYDERABAD, March 13, 2026: In 1996, Bharat Biotech was a bold idea operating out of a single facility on the fringes of Hyderabad. Today, it is the heartbeat of Asia’s largest life sciences cluster.
Celebrating its 30th anniversary today, the company, founded by Dr. Krishna Ella and Mrs. Suchitra Ella, unveiled a commemorative logo at its Genome Valley headquarters, marking its evolution from a visionary startup into a global vaccine powerhouse.
Bharat Biotech The Anchor of an Ecosystem
Every successful startup ecosystem needs an “anchor tenant,” and for Hyderabad’s Genome Valley, that was Bharat Biotech. By betting on Indian research-driven manufacturing when the sector was still in its infancy, the Ellas didn’t just build a company; they catalysed a hub that is now recognized as a global biotechnology destination.
“Thirty years ago, we started with a simple but powerful belief: that Indian science can solve global health challenges,” said Dr. Krishna Ella “Innovation with purpose has been our North Star.”
Disrupting the “Affordability” Gap
Bharat Biotech’s growth trajectory is a masterclass in high-volume, high-impact scaling. From disrupting the Hepatitis B market to launching the world’s most affordable Rotavirus vaccine at just $1 per dose, the company has consistently proven that “low cost” does not mean “low tech.”
The company’s “startup agility” was most visible during the COVID-19 pandemic. Under intense global pressure, they successfully developed COVAXIN®, India’s first indigenous COVID-19 vaccine, in a public-private partnership that became a symbol of national self-reliance.
Bharat Biotech’s Next Growth Frontier: Cell & Gene Therapy
A true innovator never stands still. As Bharat Biotech enters its fourth decade, it is pivoting toward the frontiers of biotechnology. Through its new arm, Nucelion Therapeutics, the company is moving beyond traditional vaccines into advanced cell and gene therapies.
“We built our own intellectual property because we believed India must lead, not follow,” noted Suchitra Ella. “As we enter advanced therapies, we remain guided by the same mission: science for society.”
By the Numbers: Three Decades of Scale
- 9 Billion+: Vaccine doses delivered globally.
- 125+: Countries reached.
- 220+: Patents granted, showcasing a deep-tech intellectual property moat.
- 4,000+: Employees across world-class sites in Hyderabad, Ankleshwar, and Odisha.
From the early days of a single lab to the establishment of Sapigen Biologix in Odisha, Bharat Biotech’s journey remains a blueprint for Indian startups aiming for global dominance through deep-tech innovation.
